S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
AI Stock Caught Trading Under Secret Name (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

$27.15
+3.85 (+16.52%)
(As of 02/21/2024 ET)
Today's Range
$23.68
$28.56
50-Day Range
$5.25
$29.49
52-Week Range
$2.11
$39.96
Volume
816,335 shs
Average Volume
1.39 million shs
Market Capitalization
$263.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.6% Downside
$27.00 Price Target
Short Interest
Healthy
4.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.33mentions of Corbus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$23.36 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($11.00) to ($8.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.14 out of 5 stars

Medical Sector

234th out of 932 stocks

Pharmaceutical Preparations Industry

107th out of 431 stocks


CRBP stock logo

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

CRBP Stock News Headlines

Corbus Pharmaceuticals stock: An explosive 342% YTD surge
Shares of CRBP have already experienced a meteoric rise of over 300% year-to-date, thanks to early but promising data from its Phase 1 trial.
ACAD Mar 2024 35.000 put
Shocking Bank Secret of the Ultra-Rich
A 229-year-old banking secret is behind some of the wealthiest, most powerful dynasties in American history –  here's how it could help you in 2024.
ACAD Mar 2024 36.000 call
Shocking Bank Secret of the Ultra-Rich
A 229-year-old banking secret is behind some of the wealthiest, most powerful dynasties in American history –  here's how it could help you in 2024.
Corbus Pharmaceuticals Holdings Inc
Corbus Pharma Announces Proposed Public Offering; Stock Surges
Corbus Pharmaceuticals Holding (CRBP)
Corbus Pharmaceuticals Announces Proposed Public Offering
Corbus Pharma reverses gains on common stock offering
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
2/21/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRBP
Employees
33
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$27.00
High Stock Price Target
$51.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-0.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$7.91 per share

Miscellaneous

Free Float
9,029,000
Market Cap
$263.08 million
Optionable
No Data
Beta
2.41

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 49)
    CEO & Director
    Comp: $890.67k
  • Mr. Sean F. Moran CPA (Age 66)
    M.B.A., Chief Financial Officer
    Comp: $579.05k
  • Dr. Rachael Brake Ph.D. (Age 52)
    Chief Scientific Officer
    Comp: $552.22k
  • Ted Jenkins
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Lindsey Smith
    Head of Corporate Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of Human Resources














CRBP Stock Analysis - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price target for 2024?

2 analysts have issued 1 year target prices for Corbus Pharmaceuticals' stock. Their CRBP share price targets range from $3.00 to $51.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests that the stock has a possible downside of 0.6%.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2024?

Corbus Pharmaceuticals' stock was trading at $6.04 at the beginning of 2024. Since then, CRBP stock has increased by 349.5% and is now trading at $27.15.
View the best growth stocks for 2024 here
.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 464,700 shares, an increase of 1,553.7% from the January 15th total of 28,100 shares. Based on an average daily trading volume, of 734,800 shares, the short-interest ratio is presently 0.6 days. Currently, 4.5% of the company's shares are sold short.
View Corbus Pharmaceuticals' Short Interest
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.10. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.81 million.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Royal Bank of Canada (0.23%), Dimensional Fund Advisors LP (0.38%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cormorant Asset Management, Lp, Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRBP) was last updated on 2/22/2024 by MarketBeat.com Staff